Based on our extensive clinical trial, the drug performs as a very strong anti-migraine with remarkable curative migraine effects! About 90 percent reduction of migraine headache by Migraine Spray and 93 percent of patients’ satisfaction of the treatments are remarkable achievements of the clinical trials in Phase II.
For more information, please contact
Peter Ressalehi CEO, Mim Pharma AS
+47 98 10 10 10
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which rebased, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies, and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.